TIGIT is an inhibitory receptor expressed on lymphocytes that was recently propelled under the spotlight as a major emerging target in cancer immunotherapy. TIGIT interacts with CD155 expressed on antigen-presenting cells or tumour cells to downregulate T cell and natural killer (NK) cell functions. TIGIT has emerged as a key inhibitor of anti-tumour responses that can hinder multiple steps of the cancer immunity cycle. Pre-clinical studies indicated that TIGIT blockade may protect against various solid and haematological cancers.
Specifications
Catalog Number:
KB-1041
Antibodies Name:
10A7-mIgG2a
Host Cell Line:
EXPI-CHO
Target:
Mouse-TIGIT
Species Reactivity:
Mouse
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA
Labels:
Characterization
Application
References
1.Manieri N A, Chiang E Y, Grogan J L. TIGIT: a key inhibitor of the cancer immunity cycle[J]. Trends in immunology, 2017, 38(1): 20-28.
2.He?W?,?Zhang?H?,?Han?F?,?et al?CD155T/TIGIT Signaling Regulates CD8+?T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer.?Cancer Res?2017;77:6375ÿ88.doi:10.1158/0008-5472.CAN-17-0381Y
3.Stanietsky N, Rovis TL, Glasner A, et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol. 2013;43:2138ÿ2150.
